163 related articles for article (PubMed ID: 18958459)
1. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).
Klotz U
Eur J Clin Pharmacol; 2009 Jan; 65(1):1-2. PubMed ID: 18958459
[No Abstract] [Full Text] [Related]
2. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
3. Update on the pharmacogenomics of proton pump inhibitors.
Hagymási K; Müllner K; Herszényi L; Tulassay Z
Pharmacogenomics; 2011 Jun; 12(6):873-88. PubMed ID: 21692617
[TBL] [Abstract][Full Text] [Related]
4. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacology of proton pump inhibitors.
Barone JA; Horn JR
Manag Care; 2001 Oct; 10(10 Suppl):11-6. PubMed ID: 11729442
[TBL] [Abstract][Full Text] [Related]
6. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
[TBL] [Abstract][Full Text] [Related]
7. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
9. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Park SH
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
[No Abstract] [Full Text] [Related]
10. CYP2C19 polymorphism and proton pump inhibitors.
Klotz U; Schwab M; Treiber G
Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenomical aspects of gastroesophageal reflux disease].
Isaev VA
Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
[TBL] [Abstract][Full Text] [Related]
14. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.
de Bortoli N; Martinucci I; Giacchino M; Blandizzi C; Marchi S; Savarino V; Savarino E
Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1361-9. PubMed ID: 23802731
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors in gastroesophageal reflux disease: "a custom-tailored therapeutic regimen".
Sobrino-Cossío S; López-Alvarenga JC; Remes-Troche JM; Galvis-García ES; Soto-Pérez JC; Teramoto-Matsubara O; Morales-Arámbula M; Orozco-Gamiz A; Tamayo de-la-Cuesta JL; Mateos G; Jiménez A; Sáez A; Vargas JA
Rev Esp Enferm Dig; 2012 Jul; 104(7):367-78. PubMed ID: 22849498
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
18. Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study.
Hata S; Arai M; Maruoka D; Tanaka T; Matsumura T; Suzuki T; Nakagawa T; Katsuno T; Imazeki F; Yokosuka O
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):296-301. PubMed ID: 22959094
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.
Gumus E; Karaca O; Babaoglu MO; Baysoy G; Balamtekin N; Demir H; Uslu N; Bozkurt A; Yuce A; Yasar U
Eur J Clin Pharmacol; 2012 May; 68(5):629-36. PubMed ID: 22076562
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
Ohkusa T; Maekawa T; Arakawa T; Nakajima M; Fujimoto K; Hoshino E; Mitachi Y; Hamada S; Mine T; Kawahara Y; Nagai T; Aoyama N; Yoshida N; Tadokoro K; Chida N; Konda Y; Seno H; Shimatani T; Inoue M; Sato N
Aliment Pharmacol Ther; 2005 Jun; 21(11):1331-9. PubMed ID: 15932363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]